BTMD
biote Corp.
BTMD lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
BTMD Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Under pressure | |
| Weak |
BTMD's revenue, profitability, cash flow and balance sheet are all currently under pressure.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
BTMD PE Valuation
BTMD has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
BTMD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect BTMD's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
BTMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.16 | — |
| Q3 2026 | -$0.11 | -114% |
| Q2 2026 | $0.10 | -89% |
| Q1 2026 | $0.43 | -31% |
| Q4 2025 | $0.74 | +289% |
| Q3 2025 | $0.80 | +31% |
| Q2 2025 | $0.91 | +75% |
| Q1 2025 | $0.62 | +35% |
| Q4 2024 | $0.19 | +46% |
BTMD has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
BTMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $43.3M | -9.6% |
| Q2 2026 | $44.2M | -9.5% |
| Q1 2026 | $44.9M | -8.3% |
| Q4 2025 | $46.4M | -6.9% |
| Q3 2025 | $48M | -6.7% |
| Q2 2025 | $48.9M | -0.6% |
| Q1 2025 | $49M | +4.7% |
| Q4 2024 | $49.8M | +9% |
BTMD's revenue has slid since its 2024 peak: $43M last quarter, down 9.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.7% | -12 points |
| Q2 2026 | -7.9% | -30 points |
| Q1 2026 | 7% | -13 points |
| Q4 2025 | 15% | +9.2 points |
| Q3 2025 | 17% | -6.5 points |
| Q2 2025 | 22% | +9.4 points |
| Q1 2025 | 20% | -2.5 points |
| Q4 2024 | 5.5% | -6.5 points |
BTMD has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over BTMD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
BTMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.1M | -92% |
| Q2 2026 | -$3.7M | -171% |
| Q1 2026 | $3.5M | -27% |
| Q4 2025 | $6.5M | -39% |
| Q3 2025 | $13.6M | -3.1% |
| Q2 2025 | $5.3M | -29% |
| Q1 2025 | $4.8M | -27% |
| Q4 2024 | $10.7M | +50% |
BTMD still generates free cash flow, though less than at its 2024 peak: $7M over the past year.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over BTMD on cash flow, with more consistent year-over-year improvement.
BTMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -4.2% | -1.2M shares |
| 1 year | -25% | -9.3M shares |
| 3 years | -12% | -3.6M shares |
BTMD has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.4M |
| Q2 2026 | $4.8M |
| Q1 2026 | $1.1M |
| Q4 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | $1.5M |
| Q1 2024 | $4.1M |
BTMD spent $7M buying back its own shares over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
BTMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 8.6x | High |
| Q2 2026 | 5.9x | High |
| Q1 2026 | 2.9x | Moderate |
| Q4 2025 | 2.0x | Healthy |
| Q3 2025 | 2.1x | Moderate |
| Q2 2025 | 2.2x | Moderate |
| Q1 2025 | 1.9x | Healthy |
| Q4 2024 | 1.9x | Healthy |
BTMD's net debt is about 8.6 years of its operating earnings (EBITDA), up from 2.1 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
BTMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.3 | Neutral |
| Stochastic | 6.0 | Oversold |
BTMD's weekly RSI is 32 (neutral) and its Stochastic is 6 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
BTMD PE vs Healthcare Sector
| Metric | BTMD | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 26x | 57% below |
| PE % | 73 | 36 | 37 pts above |
BTMD has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
BTMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.11 | 7.2% below |
| 20 week MA | $1.54 | 33% below |
| 50 week MA | $1.89 | 46% below |
| 100 week MA | $2.87 | 64% below |
| 200 week MA | $4.28 | 76% below |
BTMD is in a downtrend: it's below all five of its weekly moving averages, and 76% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
BTMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $10.1 | $9.85 | -2% |
| 2022 | $9.85 | $3.91 | -60% |
| 2023 | $3.91 | $4.94 | +26% |
| 2024 | $4.94 | $5.99 | +21% |
| 2025 | $5.99 | $2.68 | -55% |
| 2026 YTD | $2.68 | $1.03 | -62% |
BTMD has finished lower in three of the last five years. It's down 62% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over BTMD on returns for 2026, with the stronger performance.